<DOC>
	<DOCNO>NCT02316717</DOCNO>
	<brief_summary>This study evaluate safety preliminary efficacy two dose level IMM-124E reduce liver fat and/or serum alanine aminotransaminase ( ALT ) compare placebo .</brief_summary>
	<brief_title>A Phase Study IMM-124E Patients With Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description>Subjects provide voluntary write informed consent screen eligibility . Subjects meet inclusion none exclusion criterion eligible participate . Eligible subject randomize Baseline visit receive one three study treatment three time daily period 24 week . Each subject return study clinic assessment require study procedure Day 7 , 14 28 every 4 week thereafter Week 24 .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Provision write informed consent . 3 . Diagnosis NASH , histologically proven within 12 month Screening NASH activity score ( NAS ) 4 cytologic ballooning score least 1 ; 10 % macrovescicular steatosis . Hematoxylin &amp; Eosin ( H &amp; E ) stain slide and/or paraffin block available independent assessment . 4 . HBA1C &lt; 9.0 5 . Agree use effective contraceptive measure either male female child bear potential . 1 . Presence vascular liver disease cirrhosis ; 2 . Presence liver disease cause ( autoimmune , metabolic , medication induce ) ; 3 . BMI &lt; 25 kg/m^2 ; 4 . Alcohol use &gt; 30 g/day ; 5 . Type 1 diabetes ; 6 . 6 . History major bariatric surgery ( include balloon / sleeve gastrectomy ) ; 7 . Weight loss gain 5kg past 6 month &gt; 10 % change bodyweight past 12 month ; 8 . Contraindication MRI ; 9 . Inadequate venous access ; 10 . Lactating/breastfeeding/pregnant Screening Baseline ; 11 . HIV antibody positive , hepatitis B surface antigen positive ( HBsAg ) Hepatitis C virus ( HCV ) RNA positive ; 12 . Receiving elemental diet parenteral nutrition ; 13 . Concurrent condition Inflammatory bowel disease ; Unstable angina , myocardial infarction , transient ischemic event , stroke within 24 week Screening ; Ongoing infectious , ongoing multisystemic immunemediated and/or concurrent past malignant disease ; Any concurrent condition , opinion investigator , could impact adversely subject participate interpretation study data ; 14 . Concurrent medication include : antiNASH therapy ( ) take 10 continuous day last 3 month . These include Sadenosyl methionine ( SAMe ) , betaine , milk thistle , probiotic supplement ( yoghurt ) , vitamin E gemfibrozil . NB : If vitamin E gemfibrozil use , dose must stable liver biopsy confirm diagnosis NASH subsequent commence treatment ; commence treatment ; Wash antiNASH therapy follow : 10 day washout require , 10 day 3 month treatment require 6 week washout . Any treatment 3 month would require rebiopsy ensure histological eligibility thiazolidinediones ( glitazones ) , dipeptidyl peptidase 4 inhibitor ( gliptins ) glucagonlike peptide1 analog last 6 month . If treatment commence stable 6 month prior determinant biopsy dose still stable time study entry , subject eligible recruitment . Allowable antidiabetic treatment include metformin and/or sulfonylurea administer constant dose least 2 month prior study entry . Subjects treat Insulin eligible clinically stable insulin treatment ( i.e . recurrent acute hypo/hyperglycemic episode diagnose clinically Glucose serum level &lt; 50 mg/dL &gt; 200 mg/dL respectively ) least 2 month prior study entry . immune modulatory agent include In last 3 month : systemic steroid 7 day . daily treatment multiple nonsteroidal antiinflammatory drug ( aspirin &gt; 100mg/day , ibuprofen , naproxen , meloxicam , celecoxib ) 1 month within 3 month prior study entry ; In last 12 month : azathioprine , 6mercaptopurine , methotrexate , cyclosporin , antiTNFα therapy ( infliximab , adalimumab , etanercept ) antiintegrin therapy ( namixilab ) ; 10 consecutive day oral parenteral antibiotic within 4 week prior study entry ( Note : subject would include stool PBMC analysis ) . variable dose antilipidemic agent ( 3hydroxy3methylglutaryl ( HMG ) CoA reductase inhibitor `` statin '' ) 3 month prior study entry . 15 . The following laboratory abnormality : Neutrophil count ≤1.0 x 10^9/L Platelets &lt; 100 x 10^9/L Hemoglobin &lt; 10 g/dL Albumin &lt; 3.5 g/dL International Normalized Ratio ( INR ) &gt; 1.5 Total bilirubin &gt; 1.5 x upper limit reference range ( unless Gilbert 's syndrome extrahepatic source denote increased indirect bilirubin fraction ) Either creatinine clearance ≤60 mL/minute calculate Cockroft Gault creatinine &gt; 1.5x upper limit reference range . 16 . Known substance abuse , include inhale injected drug year prior Screening . 17 . Cow milk allergy , lactose intolerance know suspected hypersensitivity study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>